Plain-English translation of NCT03933384 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hepatitis B research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a newer medication called works just as well as an older standard treatment called for chronic hepatitis B. Both medications are antiviral pills that help control the virus, but the newer medication may be gentler on your kidneys—and researchers want to confirm this in a head-to-head comparison.
While is a proven, reliable treatment for hepatitis B, it and older versions of tenofovir can sometimes cause kidney problems with long-term use. This medication was designed to be more efficient at lower doses, which may reduce the risk of kidney damage while maintaining the same antiviral benefit.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take one of the two medications by mouth once daily for three years. Throughout the study, you'll have regular visits to check how well the medication is controlling your hepatitis B virus and to monitor your kidney and liver function through blood tests. The research team will track your progress to see which medication works best and is safest for your kidneys over the long term.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Taiwan
Phase
Post-approval monitoring
Sponsor
Taichung Veterans General Hospital
Enrollment target
~140 participants
Started
August 2019
Primary completion
December 2027
Age range
20 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Teng-Yu Lee, MD, PhD
Taichung Veterans General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.